These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 22361042)
21. Stakeholders say FDA must change REMS program. Reinke T Manag Care; 2011 Mar; 20(3):8-9. PubMed ID: 21485624 [No Abstract] [Full Text] [Related]
22. Individualizing decision-making--resurrecting the doctor-patient relationship in the anemia debate. Agarwal R Clin J Am Soc Nephrol; 2010 Jul; 5(7):1340-6. PubMed ID: 20448071 [TBL] [Abstract][Full Text] [Related]
23. Erythropoietin. A new frontier. Rutherford C J Intraven Nurs; 1991; 14(3):163-5. PubMed ID: 2033478 [TBL] [Abstract][Full Text] [Related]
24. Oncologists want FDA to rethink REMS. Goozner M J Natl Cancer Inst; 2010 Dec; 102(23):1748-9, 1751. PubMed ID: 21088276 [No Abstract] [Full Text] [Related]
25. [Guidance of FDA risk evaluation and mitigation strategy and enlightenment to drug risk management of post-marketing Chinese medicine]. Li Y; Xie Y Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2825-7. PubMed ID: 22292376 [TBL] [Abstract][Full Text] [Related]
26. Blueprint for prescriber continuing education program. Center For Drug Evaluation And Research Food And Drug Administration J Pain Palliat Care Pharmacother; 2012 Jun; 26(2):127-30. PubMed ID: 22764849 [TBL] [Abstract][Full Text] [Related]
27. Managing anemia: what do we do now? Neumann ME Nephrol News Issues; 2007 May; 21(6):50, 52. PubMed ID: 17518123 [No Abstract] [Full Text] [Related]
28. Medication guides leave their REMS programs behind. Traynor K Am J Health Syst Pharm; 2012 Feb; 69(4):272-3. PubMed ID: 22302249 [No Abstract] [Full Text] [Related]
29. Risk management of drug products and the U.S. Food and Drug Administration: evolution and context. Leiderman DB Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S9-S13. PubMed ID: 19307069 [TBL] [Abstract][Full Text] [Related]
35. The FDA black box for EPO: what should nephrologists do? Singh AK Nephrol News Issues; 2007 May; 21(6):55-6, 58-9. PubMed ID: 17518125 [No Abstract] [Full Text] [Related]
36. Risk evaluation mitigation strategies: the evolution of risk management policy. Hollingsworth K; Toscani M Popul Health Manag; 2013 Apr; 16(2):132-7. PubMed ID: 23113627 [TBL] [Abstract][Full Text] [Related]
37. Chronic renal disease and stroke in atrial fibrillation: balancing the prevention of thromboembolism and bleeding risk. Lip GY Europace; 2011 Feb; 13(2):145-8. PubMed ID: 21138929 [No Abstract] [Full Text] [Related]
38. Recombinant erythropoietin. The effect of the marketplace on socialized patient care. Besarab A; Erslev AJ ASAIO J; 1993; 39(2):85-6. PubMed ID: 8324265 [No Abstract] [Full Text] [Related]
39. Reno-cerebrovascular disease? The incognito kidney in cognition and stroke. Monk RD; Bennett DA Neurology; 2006 Jul; 67(2):196-8. PubMed ID: 16864806 [No Abstract] [Full Text] [Related]
40. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group. Nissenson AR Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]